Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
European Radiology
Published in: European Radiology 1/2018

01-01-2018 | Molecular Imaging

Non-invasive monitoring of the therapeutic response in sorafenib-treated hepatocellular carcinoma based on photoacoustic imaging

Authors: Seunghyun Lee, Jung Hoon Kim, Jae Hwan Lee, Jeong Hwa Lee, Joon Koo Han

Published in: European Radiology | Issue 1/2018

Login to get access

Abstract

Purpose

We investigated the changes of tissue oxygen saturation (sO2) in sorafenib-treated HCC (hepatocelluar carcinoma) mouse models using photoacoustic imaging (PI).

Materials and Methods

Nude mice, implanted with human HCC (HepG2-RFP) cells in the liver, were randomised to the sorafenib-treated group (n = 21) or the control group (n = 20). Tumour volume and sO2 were measured by PI at baseline and then one week later, and radiant efficiency (RE) and therapeutic response were analysed by fluorescence imaging and histologic analysis.

Results

Sorafenib was effective in treating HCC by evaluating necrotic fraction, apoptosis index, and microvessel density (MVD). One week after treatment, the sO2 of HCC and residual healthy liver tissue decreased, and the hypoxia inducible factor-1α (HIF-1α) protein expression of HCC increased, correlating with the apoptosis index. The ΔsO2 in HCC showed a significantly positive correlation with the necrotic fraction and the apoptosis index of tumour and a negative correlation with the MVD of tumour.

Conclusion

Sorafenib treatment results in changes of sO2 in HCC and liver parenchyma and induces the accumulation of HIF-1α by hypoxic environment. sO2 as measured by PI, can be a useful marker for non-invasive monitoring of the therapeutic response in orthotopic HCC mouse models.

Key Points

• Hypoxia is a characteristic feature of the tumour microenvironment
• It is important to monitor sO 2 in HCC during sorafenib treatment
• PI is useful for non-invasive monitoring of sO 2 in HCC.
• ΔsO 2 in HCC showed a significantly correlation with tumour response.
Appendix
Available only for authorised users
Literature
1.
Sun HC, Tang ZY (2004) Angiogenesis in hepatocellular carcinoma: the retrospectives and perspectives. J Cancer Res Clin Oncol 130:307–319CrossRefPubMed
2.
3.
Wigerup C, Pahlman S, Bexell D (2016) Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer. Pharmacol Ther 164:152–169CrossRefPubMed
4.
Taketomi A (2016) Clinical trials of antiangiogenic therapy for hepatocellular carcinoma. Int J Clin Oncol 21:213–218CrossRefPubMed
5.
6.
Welker MW, Trojan J (2011) Anti-angiogenesis in hepatocellular carcinoma treatment: Current evidence and future perspectives. World J Gastroenterol 17:3075–3081PubMedCentralPubMed
7.
Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390CrossRefPubMed
8.
Yamada D, Kobayashi S, Yamamoto H et al (2012) Role of the hypoxia-related gene, JMJD1A, in hepatocellular carcinoma: clinical impact on recurrence after hepatic resection. Ann Surg Oncol 19(Suppl 3):S355–364CrossRefPubMed
9.
Yip C, Blower PJ, Goh V, Landau DB, Cook GJ (2015) Molecular imaging of hypoxia in non-small-cell lung cancer. Eur J Nucl Med Mol Imaging 42:956–976CrossRefPubMed
10.
Fatema CN, Zhao SJ, Zhao Y et al (2014) Dual tracer evaluation of dynamic changes in intratumoral hypoxic and proliferative states after radiotherapy of human head and neck cancer xenografts using radiolabeled FMISO and FLT. Bmc Cancer 14
11.
Raes F, Sobilo J, Le Mee M et al (2016) High Resolution Ultrasound and Photoacoustic Imaging of Orthotopic Lung Cancer in Mice: New Perspectives for Onco-Pharmacology. Plos One 11, e0153532CrossRefPubMedCentralPubMed
12.
Gerling M, Zhao Y, Nania S et al (2014) Real-time assessment of tissue hypoxia in vivo with combined photoacoustics and high-frequency ultrasound. Theranostics 4:604–613CrossRefPubMedCentralPubMed
13.
Needles A, Heinmiller A, Sun J et al (2013) Development and initial application of a fully integrated photoacoustic micro-ultrasound system. IEEE Trans Ultrason Ferroelectr Freq Control 60:888–897CrossRefPubMed
14.
Rich LJ, Seshadri M (2015) Photoacoustic imaging of vascular hemodynamics: validation with blood oxygenation level-dependent MR imaging. Radiology 275:110–118CrossRefPubMed
15.
Murakami M, Zhao S, Zhao Y et al (2012) Evaluation of changes in the tumor microenvironment after sorafenib therapy by sequential histology and 18F-fluoromisonidazole hypoxia imaging in renal cell carcinoma. Int J Oncol 41:1593–1600CrossRefPubMedCentralPubMed
16.
Wilhelm SM, Carter C, Tang L et al (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099–7109CrossRefPubMed
17.
Ayers GD, McKinley ET, Zhao P et al (2010) Volume of Preclinical Xenograft Tumors Is More Accurately Assessed by Ultrasound Imaging Than Manual Caliper Measurements. J Ultrasound Med 29:891–901CrossRefPubMedCentralPubMed
18.
Zhou J, Zheng W, Cao L, Liu M, Han F, Li A (2010) Antiangiogenic tumor treatment: noninvasive monitoring with contrast pulse sequence imaging for contrast-enhanced grayscale ultrasound. Acad Radiol 17:646–651CrossRefPubMed
19.
Yamashita YI, Shimada M, Hasegawa H et al (2001) Electroporation-mediated interleukin-12 gene therapy for hepatocellular carcinoma in the mice model. Cancer Res 61:1005–1012PubMed
20.
21.
Degasperi A, Birtwistle MR, Volinsky N, Rauch J, Kolch W, Kholodenko BN (2014) Evaluating strategies to normalise biological replicates of Western blot data. Plos One 9, e87293CrossRefPubMedCentralPubMed
22.
Laufer J, Delpy D, Elwell C, Beard P (2007) Quantitative spatially resolved measurement of tissue chromophore concentrations using photoacoustic spectroscopy: application to the measurement of blood oxygenation and haemoglobin concentration. Phys Med Biol 52:141–168CrossRefPubMed
23.
Mallidi S, Watanabe K, Timerman D, Schoenfeld D, Hasan T (2015) Prediction of Tumor Recurrence and Therapy Monitoring Using Ultrasound-Guided Photoacoustic Imaging. Theranostics 5:289–301CrossRefPubMedCentralPubMed
24.
Miyata A, Ishizawa T, Kamiya M, 9 et al (2014) Photoacoustic Tomography of Human Hepatic Malignancies Using Intraoperative Indocyanine Green Fluorescence Imaging. Plos One 7:9(11):e112667CrossRef
25.
26.
Chang YS, Adnane J, Trail PA et al (2007) Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol 59:561–574CrossRefPubMed
27.
Chen Y, Huang Y, Reiberger T et al (2014) Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice. Hepatology 59:1435–1447CrossRefPubMedCentralPubMed
28.
Liang YJ, Zheng TS, Song RP et al (2013) Hypoxia-Mediated Sorafenib Resistance Can Be Overcome by EF24 Through Von Hippel-Lindau Tumor Suppressor-Dependent HIF-1 alpha Inhibition in Hepatocellular Carcinoma. Hepatology 57:1847–1857CrossRefPubMed
29.
Xu HT, Zhao L, Fang QJ et al (2014) MiR-338-3p Inhibits Hepatocarcinoma Cells and Sensitizes These Cells to Sorafenib by Targeting Hypoxia-Induced Factor 1 alpha. Plos One 9
30.
Liu LP, Ho RLK, Chen GG, Lai PBS (2012) Sorafenib Inhibits Hypoxia-Inducible Factor-1 alpha Synthesis: Implications for Antiangiogenic Activity in Hepatocellular Carcinoma. Clin Cancer Res 18:5662–5671CrossRefPubMed
31.
Zheng X, Wang X, Mao H, Wu W, Liu B, Jiang X (2015) Hypoxia-specific ultrasensitive detection of tumours and cancer cells in vivo. Nat Commun 6:5834CrossRefPubMed
32.
Harada H, Inoue M, Itasaka S et al (2012) Cancer cells that survive radiation therapy acquire HIF-1 activity and translocate towards tumour blood vessels. Nature Communications 3
33.
Kim KR, Moon HE, Kim KW (2002) Hypoxia-induced angiogenesis in human hepatocellular carcinoma. J Mol Med (Berl) 80:703–714CrossRef
34.
35.
Hu F, Deng X, Yang X et al (2015) Hypoxia upregulates Rab11-family interacting protein 4 through HIF-1 alpha to promote the metastasis of hepatocellular carcinoma. Oncogene 34:6007–6017CrossRefPubMed
36.
Li H, Chen J, Zen W et al (2015) Effect of hypoxia inducible factor-1 antisense oligonucleotide on liver cancer. Int J Clin Exp Med 8:12650–12655PubMedCentralPubMed
37.
Unruh A, Ressel A, Mohamed HG et al (2003) The hypoxia-inducible factor-1 alpha is a negative factor for tumor therapy. Oncogene 22:3213–3220CrossRefPubMed
38.
Sugimoto K, Moriyasu F, Saito K et al (2013) Hepatocellular carcinoma treated with sorafenib: early detection of treatment response and major adverse events by contrast-enhanced US. Liver Int 33:605–615CrossRefPubMed
39.
Mejias M, Garcia-Pras E, Tiani C, Miquel R, Bosch J, Fernandez M (2009) Beneficial Effects of Sorafenib on Splanchnic, Intrahepatic, and Portocollateral Circulations in Portal Hypertensive and Cirrhotic Rats. Hepatology 49:1245–1256CrossRefPubMed
40.
Wilhelm S, Carter C, Lynch M et al (2006) Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 5:835–844CrossRefPubMed
41.
Yang XZ, Dou S, Sun TM, Mao CQ, Wang HX, Wang J (2011) Systemic delivery of siRNA with cationic lipid assisted PEG-PLA nanoparticles for cancer therapy. J Control Release 156:203–211CrossRefPubMed
42.
Yan CH, Yang M, Li ZZ et al (2014) Suppression of orthotopically implanted hepatocarcinoma in mice by umbilical cord-derived mesenchymal stem cells with sTRAIL gene expression driven by AFP promoter. Biomaterials 35:3035–3043CrossRefPubMed
43.
Ben Mousa A (2008) Sorafenib in the treatment of advanced hepatocellular carcinoma. Saudi J Gastroenterol 14:40–42CrossRefPubMed
44.
Metadata
Title
Non-invasive monitoring of the therapeutic response in sorafenib-treated hepatocellular carcinoma based on photoacoustic imaging
Authors
Seunghyun Lee
Jung Hoon Kim
Jae Hwan Lee
Jeong Hwa Lee
Joon Koo Han
Publication date
01-01-2018
Publisher
Springer Berlin Heidelberg
Published in
European Radiology / Issue 1/2018
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-017-4960-3

Other articles of this Issue 1/2018

European Radiology 1/2018 Go to the issue

Urogenital

Assessment of acute kidney injury with T1 mapping MRI following solid organ transplantation

Chest

Software-based risk stratification of pulmonary adenocarcinomas manifesting as pure ground glass nodules on computed tomography

Oncology

Multi-parametric MRI in cervical cancer: early prediction of response to concurrent chemoradiotherapy in combination with clinical prognostic factors

Computed Tomography

The effect of iodine uptake on radiation dose absorbed by patient tissues in contrast enhanced CT imaging: Implications for CT dosimetry

Interventional

Improving mTICI2b reperfusion to mTICI2c/3 reperfusions: A retrospective observational study assessing technical feasibility, safety and clinical efficacy

Magnetic Resonance

Ferumoxytol-enhanced magnetic resonance angiography for the assessment of potential kidney transplant recipients